Analysts predict that Cooper Companies Inc (NYSE:COO) will post earnings per share of $3.16 for the current quarter, Zacks Investment Research reports. Ten analysts have made estimates for Cooper Companies’ earnings, with the highest EPS estimate coming in at $3.20 and the lowest estimate coming in at $3.11. Cooper Companies reported earnings of $3.00 per share during the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The firm is scheduled to issue its next earnings results after the market closes on Thursday, August 29th.
On average, analysts expect that Cooper Companies will report full-year earnings of $12.28 per share for the current fiscal year, with EPS estimates ranging from $12.20 to $12.40. For the next fiscal year, analysts anticipate that the firm will post earnings of $13.30 per share, with EPS estimates ranging from $13.07 to $13.65. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Cooper Companies.
Cooper Companies (NYSE:COO) last issued its earnings results on Thursday, May 30th. The medical device company reported $2.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.76 by $0.18. The firm had revenue of $654.30 million for the quarter, compared to analysts’ expectations of $655.00 million. Cooper Companies had a net margin of 16.46% and a return on equity of 17.25%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.86 earnings per share.
Shares of NYSE:COO opened at $340.18 on Friday. The company has a 50 day moving average price of $333.93. The firm has a market capitalization of $16.67 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 2.55 and a beta of 0.90. Cooper Companies has a fifty-two week low of $228.65 and a fifty-two week high of $344.32. The company has a current ratio of 1.21, a quick ratio of 0.68 and a debt-to-equity ratio of 0.42.
The firm also recently disclosed a Semi-Annual dividend, which was paid on Wednesday, August 7th. Investors of record on Tuesday, July 23rd were paid a $0.03 dividend. The ex-dividend date was Monday, July 22nd. Cooper Companies’s dividend payout ratio is currently 0.52%.
In related news, Director Gary S. Petersmeyer sold 355 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $323.92, for a total value of $114,991.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Daniel G. Mcbride sold 11,981 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $315.99, for a total value of $3,785,876.19. Following the sale, the chief operating officer now directly owns 42,668 shares of the company’s stock, valued at $13,482,661.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 77,678 shares of company stock valued at $25,063,536. Company insiders own 1.70% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. National Pension Service increased its holdings in shares of Cooper Companies by 7.4% during the 2nd quarter. National Pension Service now owns 70,925 shares of the medical device company’s stock valued at $23,894,000 after acquiring an additional 4,875 shares during the last quarter. Rampart Investment Management Company LLC lifted its holdings in shares of Cooper Companies by 947.9% in the second quarter. Rampart Investment Management Company LLC now owns 6,298 shares of the medical device company’s stock valued at $2,122,000 after purchasing an additional 5,697 shares in the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of Cooper Companies by 6.9% in the second quarter. Asset Management One Co. Ltd. now owns 24,833 shares of the medical device company’s stock valued at $8,365,000 after purchasing an additional 1,606 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Cooper Companies in the second quarter valued at about $34,000. Finally, Atlanta Capital Management Co. L L C lifted its holdings in shares of Cooper Companies by 0.6% in the second quarter. Atlanta Capital Management Co. L L C now owns 107,021 shares of the medical device company’s stock valued at $36,054,000 after purchasing an additional 663 shares in the last quarter. 96.10% of the stock is owned by institutional investors.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Article: What are the economic characteristics of a bear market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.